<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418418</url>
  </required_header>
  <id_info>
    <org_study_id>TYH 6220</org_study_id>
    <nct_id>NCT00418418</nct_id>
  </id_info>
  <brief_title>Combined CABG and Stem-Cell Transplantation for Heart Failure</brief_title>
  <official_title>Combined CABG and Stem-Cell Transplantation for Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Helsinki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective double blind trial of intraoperative transmyocardial bone&#xD;
      marrow-derived mesenchymal cell transplantation vs placebo in patients with low left&#xD;
      ventricular ejection fraction scheduled to coronary bypass operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of symptomatic heart failure in general population is up to 2% and the&#xD;
      prevalence increases rapidly with age. Half of the patients with symptomatic heart failure&#xD;
      will die within 4 years of diagnosis.The purpose of this study is to examine the effect of&#xD;
      bone marrow-derived stem cell transplantation in left ventricular ejection fraction.&#xD;
&#xD;
      Consecutive patients with systolic heart failure (n=60), with ischemic coronary heart&#xD;
      disease, scheduled to by-pass-operation (CABG) will be collected from cardiovascular&#xD;
      laboratory and outpatient clinic of Helsinki University Central Hospital. Patients should&#xD;
      have heart failure with ejection fraction between 15 to 45%. Randomly patients are selected&#xD;
      to receive a stem cell transplantation with best possible heart failure medication, or&#xD;
      without cell transplantation. In this study, 30 patients are receiving bone marrow&#xD;
      transplantation, and 30 patients are serving as a control population. All patients will&#xD;
      receive CABG.The study will be carried out with randomized, double blind techniques for one&#xD;
      year. Randomization (in blocks) will be based on a table of random numbers.Bone marrow and&#xD;
      patients own serum will be blinded by using colored syringe, so that the doctor transfusing&#xD;
      the sample, will not be able to know the nature of the sample. From all patients, a right&#xD;
      atrial biopsy will be collected for assessment of autologous cardiac stem cells. Also sample&#xD;
      of pericardial fluid will be collected for measures of growth factors.&#xD;
&#xD;
      Comparisons: Preoperatively, patients will be imagined by cardiac ultrasound, cardiac MRI,&#xD;
      cardiac PET and SPECT. Serum pro-BNB samples will be collected. Postoperatively at 3 months&#xD;
      and 6 months pro-BNB and cardiac ultrasound will be evaluated. At one year cardiac&#xD;
      ultrasound, cardiac MRI, cardiac PET and SPECT will be reassessed.&#xD;
&#xD;
      Heart failure and coronary artery disease treatments beside the transplantation will be&#xD;
      optimized according to the judgment of the doctors of the outpatients clinic. Primary&#xD;
      endpoint of the study is the change of ejection fraction in MRI images.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Does a bone marrow transplantation therapy increase the ejection fraction of the heart measured with MRI, when compared with placebo treatment?</measure>
    <time_frame>1 year after the transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy increase any cardiac function parameter measured by a an echocardiography, MRI or PET ischemia area, when compared with no treatment group?</measure>
    <time_frame>6 months and 1 year after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy improve BNP-value?</measure>
    <time_frame>3kk, 6 months and 1 year after the procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does a bone marrow transplantation therapy decrease hospitalization or the days stayed in hospital?</measure>
    <time_frame>primary hospital stay after the transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does pericardial fluid growth factor concentrations correlate to left ventricular function improvement?</measure>
    <time_frame>up to 1 year after the translantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Does autologous cardiac stem cell quality correlate to left ventricular function improvement?</measure>
    <time_frame>3kk, 6 months and 1 year after the transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient group receiving the stem cell injections during the CABG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient group receiving autologous serum injections during the CAGB operation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary bypass operation</intervention_name>
    <description>Coronary bypass operation is performed via sternotomy during cardiac arrest.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>CABG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow aspiration (crista iliaca)</intervention_name>
    <description>The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Stem cell harvest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial mesenchymal stem cell transplantation</intervention_name>
    <description>During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Stem cell therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intramyocardial injection of autologous serum</intervention_name>
    <description>Intramyocardial injection of autologous serum is injected during cardiac arrest</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Stem cell control therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General (patients must have all)&#xD;
&#xD;
               -  Symptomatic heart failure.&#xD;
&#xD;
               -  Scheduled to CABG&#xD;
&#xD;
               -  Be 18 to 75 years of age&#xD;
&#xD;
               -  Informed Consent obtained&#xD;
&#xD;
          -  Heart Failure Presentation&#xD;
&#xD;
               -  Patients of either gender, who has evaluated in cardiovascular laboratory and&#xD;
                  scheduled to CABG with moderate heart failure, will be eligible&#xD;
&#xD;
               -  NYHA II-IV symptoms&#xD;
&#xD;
               -  Left ventricular ejection fraction in screening echocardiography 15 to 45%.&#xD;
&#xD;
               -  Optimal heart failure medication and coronary medication before operation,&#xD;
                  containing at least two heart failure drugs: must have ACE-inhibitor, or AT II&#xD;
                  blocker, and/or b-blocker together with diuretics, digitalis or aldosterone&#xD;
                  antagonist, and coronary medication: a statin and anticoagulation, either aspirin&#xD;
                  or clopidogrel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure due to left ventricular outflow track obstruction (valve problem or&#xD;
             HOCM)&#xD;
&#xD;
          -  History of life-threatening ventricular arrhythmias or resuscitation, condition which&#xD;
             may be repeatable or implanted ICD.&#xD;
&#xD;
          -  Stroke or other disabling condition with in 3 months before screening&#xD;
&#xD;
          -  Contraindications to coronary angiogram or MRI&#xD;
&#xD;
          -  Other serious disease limiting life expectancy&#xD;
&#xD;
          -  Participation in an other clinical trial&#xD;
&#xD;
          -  Severe valve disease: mitral, aortic, tricuspid or pulmonic stenosis / insufficiency&#xD;
&#xD;
          -  Scheduled valve operation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Harjula, MD; PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiothoracic Surgery, Helsinki University MeilahtiHospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Harjula, MD,PhD</last_name>
    <phone>+3585064814</phone>
    <email>ari.harjula@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tommi Pätilä, MD</last_name>
    <phone>+358504272291</phone>
    <email>tommi.patila@hus.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiothoracic Surgery, Meilahti Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029-HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Harjula, MD, PhD</last_name>
      <phone>+5042764814</phone>
      <email>ari.harjula@hus.fi</email>
    </contact>
    <contact_backup>
      <last_name>Tommi Pätilä, MD, PhD</last_name>
      <phone>+358504272291</phone>
      <email>tommi.patila@hus.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Ari Harjula, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tommi Pätilä, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sinisalo Juha, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Vento, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mika Laine, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pekka Hämmäinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esko Kankuri, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reino Pöyhiä, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raili Suojaranta-Ylinen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aapo Ahonen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jorma Sipponen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markku Kupari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riitta Alitalo, MD; PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>January 3, 2007</study_first_submitted>
  <study_first_submitted_qc>January 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2007</study_first_posted>
  <last_update_submitted>August 18, 2008</last_update_submitted>
  <last_update_submitted_qc>August 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Reijo Haapiainen</name_title>
    <organization>Helsinki University Hospital</organization>
  </responsible_party>
  <keyword>Cell transplantation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

